We make use of an inducible cardiomyocyte-specific promoter crossed to R26 Confetti to allow us to study cardiomyocytes proliferation within the heart

van Rooij: Molecular Cardiology

Back to research groups

The Van Rooij group aims to delineate signaling pathways relevant for heart repair and remodeling that can eventually lead to effective treatment options to minimize the loss of cardiomyocytes and/or reverse the adverse remodeling processes in the diseased heart.

A major challenge in the field of cardiac biology is to decipher the relevance of different signaling mechanisms that are relevant during disease. Using mouse genetics in combination with novel sequencing technologies our lab is able to identify key cell types or candidate factors important for specific remodeling and repair processes of the heart. These factors are studied in detail by molecular gain and loss-of-function studies, applying both genetics and oligonucleotide-based approaches.

Key publications

Desmosomal protein degradation as an underlying cause of arrhythmogenic cardiomyopathy

Tsui H, van Kampen SJ, Han SJ, Meraviglia V, van Ham WB, Casini S, van der Kraak P, Vink A, Yin X, Mayr M, Bossu A, Marchal GA, Monshouwer-Kloots J, Eding J, Versteeg D, de Ruiter H, Bezstarosti K, Groeneweg J, Klaasen SJ, van Laake LW, Demmers JAA, Kops GJPL, Mummery CL, van Veen TAB, Remme CA, Bellin M, van Rooij E.

Sci. Transl. Med.

Download|2023

Cardiomyocytes stimulate angiogenesis after ischemic injury in a ZEB2-dependent manner

Monika M Gladka, Arwa Kohela, Bas Molenaar, Danielle Versteeg, Lieneke Kooijman, Jantine Monshouwer-Kloots, Veerle Kremer, Harmjan R Vos, Manon M H Huibers, Jody J Haigh, Danny Huylebroeck, Reinier A Boon, Mauro Giacca, Eva van Rooij

Nat. Commun.

Download|2021

Epicardial differentiation drives fibro-fatty remodeling in arrhythmogenic cardiomyopathy

Arwa Kohela, Sebastiaan J. van Kampen, Tara Moens, Martijn Wehrens, Bas Molenaar, Cornelis J. Boogerd, Jantine Monshouwer-Kloots, Ilaria Perini, Marie José Goumans, Anke M. Smits, J. Peter van Tintelen, and Eva van Rooij.

Sci. Transl. Med.

Download|2021

Single-cell transcriptomics provides insights into hypertrophic cardiomyopathy

Wehrens M, de Leeuw AE, Wright-Clark M, Eding JEC, Boogerd CJ, Molenaar B, van der Kraak PH, Kuster DWD, van der Velden J, Michels M, Vink A, van Rooij E.

Cell Rep.

Download|2022

PITX2 induction leads to impaired cardiomyocyte function in arrhythmogenic cardiomyopathy

van Kampen SJ, Han SJ, van Ham WB, Kyriakopoulou E, Stouthart EW, Goversen B, Monshouwer-Kloots J, Perini I, de Ruiter H, van der Kraak P, Vink A, van Laake LW, Groeneweg JA, de Boer TP, Tsui H, Boogerd CJ, van Veen TAB, van Rooij E

Stem Cell Rep.

Download|2023

Thymosin β4 and prothymosin α promote cardiac regeneration post-ischemic injury in mice

Monika M Gladka, Anne Katrine Z Johansen, Sebastiaan J van Kampen, Marijn M C Peters, Bas Molenaar, Danielle Versteeg, Lieneke Kooijman, Lorena Zentilin, Mauro Giacca, Eva van Rooij

Cardiovasc. Res.

Download|2022

Spatial transcriptomics unveils ZBTB11 as a regulator of cardiomyocyte degeneration in arrhythmogenic cardiomyopathy

Boogerd CJ, Lacraz GPA 1, Vértesy A, van Kampen SJ, Perini I, de Ruiter H, Versteeg D, Brodehl A, van der Kraak PH, Giacca M, de Jonge N, Junker JP, van Oudenaarden A, Vink A, van Rooij E.

Cardiovasc. Res.

Download|2022

Single-cell transcriptomics following ischemic injury identifies a role for B2M in cardiac repair

Molenaar B, Timmer LT, Droog M, Perini I, Versteeg D, Kooijman L, Monshouwer-Kloots J, de Ruiter H, Gladka MM, van Rooij E

Commsbio.

Download|2021

Single-cell sequencing of the healthy and diseased heart reveals Ckap4 as a new modulator of fibroblasts activation.

Gladka MM, Molenaar B, de Ruiter H, Versteeg D, Lacraz GPA, van der Elst S, Huibers MMH, van Oudenaarden A, van Rooij E.

Circulation

Download|2018

Tomo-seq identifies SOX9 as a key regulator of cardiac fibrosis during ischemic injury.

Lacraz GPA, Junker JP, Gladka MM, Molenaar B, Scholman KT, Vigil-Garcia M, Versteeg D, de Ruiter H, Vermunt MW, Creyghton MP, Huibers MMH, de Jonge N, van Oudenaarden A, van Rooij E.

Circulation

Download|2017

Postnatal cardiac gene-editing using CRISPR/Cas9 with AAV9-mediated delivery of short guide RNAs results in mosaic gene disruption.

Johansen AK, Molenaar B, Versteeg D, Leitoguinho AR, Demkes CJ, Spanjaard B, de Ruiter H, Akbari Moqadam FA, Kooijman L, Zentilin L, Giacca M, van Rooij E.

Circ. Res.

Download|2017

Control of stress-dependent cardiac growth and gene expression by a microRNA.

van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN.

Science

Download|2007

Gene expression profiling of hypertrophic cardiomyocytes identifies new players in pathological remodeling

Marta Vigil-Garcia, Charlotte J Demkes, Joep E C Eding, Danielle Versteeg, Hesther de Ruiter, Ilaria Perini, Lieneke Kooijman, Monika M Gladka, Folkert W Asselbergs, Aryan Vink, Magdalena Harakalova, Alexander Bossu, Toon A B van Veen, Cornelis J Boogerd, Eva van Rooij

Cardiovasc. Res.

Download|2020

CRISPR Craze to Transform Cardiac Biology

Sebastiaan Johannes van Kampen, Eva van Rooij

Trends. Mol. Med.

2019

The efficacy of cardiac anti-miR-208a therapy is stress dependent.

Eding JE, Demkes CJ, Lynch JM, Seto AG, Montgomery RL, Semus HM, Jackson AL, Isabelle M, Chimenti S, van Rooij E.

Mol. Ther.

Download|2017

MicroRNA mimicry blocks pulmonary fibrosis.

Montgomery RL, Yu G, Latimer PA, Stack C, Robinson K, Dalby CM, Kaminski N, van Rooij E

EMBO Mol. Med.

Download|2014

Inhibition of miR-15 protects against cardiac ischemic injury.

Hullinger TG, Montgomery RL, Seto AG, Dickinson BA, Semus HM, Lynch JM, Dalby CM, Robinson K, Stack C, Latimer PA, Hare JM, Olson EN, van Rooij E.

Circ. Res.

Download|2012

Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure.

Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, Stack C, Latimer PA, Olson EN, van Rooij E.

Circulation

Download|2011

Group leader

Eva van Rooij

Eva van Rooij is group leader at the Hubrecht Institute and professor of Molecular Cardiology at the University Medical Center Utrecht. Her group aims to unveil the molecular signaling pathways that are relevant for cardiac disease. The Van Rooij group combines mouse genetics and models of heart disease with novel sequencing technologies such as single-cell sequencing and Tomo-seq to identify key cell types or candidate factors important for specific remodeling and repair processes of the heart. The ultimate goal is to identify pathways that can eventually lead to effective treatment options to minimize the loss of cardiomyocytes and/or reverse the adverse remodeling processes in the diseased heart.

Scientific training and positions

Awards

Current other activities


Group members

Eva van Rooij

Group Leader

Hesther de Ruiter

Technician

Jantine Monshouwer-Kloots

Technician

Ilaria Perini

Technician

Ceren Agirman

Technician

Katalin Dorner

Technician

Kees Jan Boogerd

Postdoc

Jenny Tsui

Postdoc

Martijn Wehrens

Postdoc

Tim Koopmans

Postdoc

Pablo Montanes

Postdoc

Su Ji Han

PhD Student

Eirini Kyriakopoulou

PhD Student

Alejandro Cardona

PhD Student

Thomas Monnikhof

PhD Student

Elvira den Hertog

PhD Student

Laura Stumpo

PhD Student

Valeria Ghezzi

PhD Student

Show all group members

Lab alumni